Angela Ravenda

Dr. Angela Ravenda


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2025 in Molecules
Verified
Journal Article
Open access
PDF file
RGRosaria Gitto
Rosaria Gitto
LLLisa Lombardo
Lisa Lombardo
ARAngela Ravenda
Angela Ravenda
FBFrancesco Broccolo
Francesco Broccolo
Antonio MastinoAntonio Mastino
Antonio Mastino
FMFrancesca Marino-Merlo
Francesca Marino-Merlo
Neuraminidase (NA) decorates the surface of the influenza virus, exerting a sialidase activity that enables the viral particle to be released in the host cell. Numerous sialic-based antiviral agents competitively bind to the NA cavity and are marketed worldwide for the treatment of Influenza A infection. We designed and validated a structure-based pharmacophore model for influenza neuraminidase (NA), which guided a virtual screening campaign against an in-house library of compounds already available for testing. This fast and cost-effective in silico strategy resulted in the identification of seven candidates possessing indole or isoquinoline chemical core. In vitro assays confirmed their favorable cytotoxicity profiles and identified only one, the 1-(1H-indol-3-ylcarbonyl)-3-piperidinecarboxylic acid (1), with reproducible inhibitory activity toward NA at non-cytotoxic concentrations. This work suggested a validated workflow for the discovery of novel NA inhibitors and highlighted an indole-based hit compound as a starting point for further optimization.